Amivantamab and Lazertinib in Untreated EGFR-Mutated Advanced NSCLC
1. The progression-free survival between the amivantamab–lazertinib group (23.7 months) and the osimertinib group (16.6 months) had an HR 0.70....
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced NSCLC
1. Patients with no biochemical or radiographic evidence of progressive disease had a median treatment break of 20.3 months. 2....
Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colon Cancer
1. No disease recurrences were observed during the median follow-up time of 26.2 months. 2. Immune-related adverse events grade 3-4...
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
1. The event-free survival at 12 months was 83.7% in the neoadjuvant group vs 57.2% in the adjuvant group. 2....
Perioperative Nivolumab in Resectable Lung Cancer
1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the chemotherapy group with HR...
Trastuzumab Deruxtecan in Solid Tumours Harbouring HER2 Mutations
1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse event grade 3 or higher was seen...
Gefitinib with Chemotherapy in EGFR-Mutated Lung Cancer
1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the gefitinib plus chemotherapy...
Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with...
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion axillary lymph node dissection was...
Neoadjuvant Dual vs Single Checkpoint Inhibitors in High-Risk Melanoma
1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single checkpoint inhibitors. 2. The...
